Warning: The NCBI web site requires JavaScript to function. more...
Drotrecogin alfa (activated): down and not out, but not really in either.
Friedrich JO, Adhikari NK, Meade MO.
Crit Care. 2006;10(5):420. No abstract available.
Related citations
Benefit-risk assessment of drotrecogin alfa (activated) in the treatment of sepsis.
De Backer D.
Drug Saf. 2007;30(11):995-1010. Review.
A case series of drotrecogin alfa (activated) in lung transplant recipients.
Daniels TL, Dummer JS, Bernard GR, Milstone AP.
Transplantation. 2006 Jun 27;81(12):1739-42.
Drotrecogin alfa (activated) in the treatment of severe sepsis.
Vincent JL.
Expert Rev Anti Infect Ther. 2006 Aug;4(4):537-47. Review.
Drotrecogin alfa (activated) in severe sepsis.
Tsalis K.
Med Sci Monit. 2004 Oct;10(10):LE19. Epub 2004 Sep 23. No abstract available.
Steroids and drotrecogin alfa (activated) for severe sepsis.
Steingrub JS.
Chest. 2003 Nov;124(5):2033. No abstract available.
Drotrecogin alfa: a second look. More clinical trials in severe sepsis: mostly negative results.
[No authors listed]
Prescrire Int. 2007 Feb;16(87):7-9.
Use of drotrecogin alfa (activated) for severe sepsis in New Jersey acute care hospitals.
Dombrovskiy V, Martin A, Sunderram J, Paz H.
Am J Health Syst Pharm. 2006 Jun 15;63(12):1151-6.
Introduction: severe sepsis and drotrecogin alfa (activated).
Artigas A, Martin CD.
Crit Care. 2007;11 Suppl 5:S1. No abstract available.
LaRosa SP.
N Engl J Med. 2006 Jan 5;354(1):94-6; author reply 94-6. No abstract available.
Baillie JK, Murray G.
Safety, pharmacokinetics, and pharmacodynamics of drotrecogin alfa (activated) in children with severe sepsis.
Weiss KD.
Pediatrics. 2004 Jan;113(1 Pt 1):134. No abstract available.
Drotrecogin alfa (activated): current evidence supports treatment for severe sepsis patients with a high risk of death.
Williams MD, Janes JM, Nelson DR.
Crit Care. 2006;10(5):424. No abstract available.
Drotrecogin alfa (activated): diffusion from clinical trials to clinical practice.
Ridley S, Lwin A, Wyncoll D, Lippett S, Watson D, Gunning K, Higgins D.
Eur J Anaesthesiol. 2008 Mar;25(3):211-6. Epub 2007 Nov 22.
The use of drotrecogin alfa recombinant activated protein C for severe sepsis in the critically burned patient: a new treatment approach.
Weintraub J, Satterwhite T, Allo M.
Burns. 2006 Sep;32(6):783-7. Epub 2006 Aug 1. No abstract available.
Drotrecogin alfa (activated) in patients with severe sepsis and a high risk of death.
Crit Care. 2006;10(6):427. No abstract available.
Effectiveness of drotrecogin alfa (activated) in clinical practice: a stitch in time.
Doig G.
Crit Care Med. 2008 Jan;36(1):332-3. No abstract available.
Curr Drug Saf. 2007 Sep;2(3):227-31. Review.
Drotrecogin alfa activated as a treatment for severe sepsis in pediatric cancer.
Russo G, La Spina M, Disma N, Astuto M.
Bone Marrow Transplant. 2006 Oct;38(8):575-6. Epub 2006 Aug 21. No abstract available.
[Identification of surgical patients for therapy with activated Drotrecogin alfa].
Utzolino S, Baier P, Hopt UT.
Anaesthesist. 2006 Jun;55 Suppl 1:30-5. Review. German.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on